JP6082737B2 - がんを治療するためのシステム、方法、および製剤 - Google Patents

がんを治療するためのシステム、方法、および製剤 Download PDF

Info

Publication number
JP6082737B2
JP6082737B2 JP2014519082A JP2014519082A JP6082737B2 JP 6082737 B2 JP6082737 B2 JP 6082737B2 JP 2014519082 A JP2014519082 A JP 2014519082A JP 2014519082 A JP2014519082 A JP 2014519082A JP 6082737 B2 JP6082737 B2 JP 6082737B2
Authority
JP
Japan
Prior art keywords
pharmaceutical formulation
cancer
epigenetic
patients
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014519082A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014518274A5 (enExample
JP2014518274A (ja
Inventor
ニザーミー、エムディー、モハマッド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Cancer Institute Of America
Original Assignee
Research Cancer Institute Of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Cancer Institute Of America filed Critical Research Cancer Institute Of America
Publication of JP2014518274A publication Critical patent/JP2014518274A/ja
Publication of JP2014518274A5 publication Critical patent/JP2014518274A5/ja
Application granted granted Critical
Publication of JP6082737B2 publication Critical patent/JP6082737B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Inorganic Chemistry (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2014519082A 2011-07-07 2012-07-06 がんを治療するためのシステム、方法、および製剤 Active JP6082737B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161505393P 2011-07-07 2011-07-07
US61/505,393 2011-07-07
US201161507950P 2011-07-14 2011-07-14
US61/507,950 2011-07-14
PCT/US2012/045821 WO2013006821A1 (en) 2011-07-07 2012-07-06 Systems, methods, and formulations for treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017009055A Division JP6401317B2 (ja) 2011-07-07 2017-01-23 がんを治療するためのシステム、方法、および製剤

Publications (3)

Publication Number Publication Date
JP2014518274A JP2014518274A (ja) 2014-07-28
JP2014518274A5 JP2014518274A5 (enExample) 2015-08-13
JP6082737B2 true JP6082737B2 (ja) 2017-02-15

Family

ID=47437478

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014519082A Active JP6082737B2 (ja) 2011-07-07 2012-07-06 がんを治療するためのシステム、方法、および製剤
JP2017009055A Active JP6401317B2 (ja) 2011-07-07 2017-01-23 がんを治療するためのシステム、方法、および製剤
JP2018166950A Pending JP2018203767A (ja) 2011-07-07 2018-09-06 がんを治療するためのシステム、方法、および製剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017009055A Active JP6401317B2 (ja) 2011-07-07 2017-01-23 がんを治療するためのシステム、方法、および製剤
JP2018166950A Pending JP2018203767A (ja) 2011-07-07 2018-09-06 がんを治療するためのシステム、方法、および製剤

Country Status (13)

Country Link
US (3) US20130011488A1 (enExample)
EP (2) EP3326625A1 (enExample)
JP (3) JP6082737B2 (enExample)
KR (2) KR102020939B1 (enExample)
CN (2) CN109675041A (enExample)
AU (2) AU2012278813B2 (enExample)
CA (1) CA2839727C (enExample)
ES (1) ES2630306T3 (enExample)
IN (1) IN2014DN00195A (enExample)
MX (1) MX354383B (enExample)
PL (1) PL2729008T3 (enExample)
RU (1) RU2644635C2 (enExample)
WO (1) WO2013006821A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933078B2 (en) 2011-07-14 2015-01-13 Research Cancer Institute Of America Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances
CA2861047A1 (en) * 2012-01-18 2013-07-25 Concert Pharmaceuticals, Inc. Deuterated alpha-lipoic acid
CN103877066B (zh) * 2014-02-21 2016-08-24 中国人民解放军第二军医大学 载多西他赛和莱菔硫烷的自组装纳米粒的制备方法与应用
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
US11890292B2 (en) 2017-02-27 2024-02-06 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
WO2018170457A1 (en) * 2017-03-17 2018-09-20 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
ES3012841T3 (en) * 2017-10-06 2025-04-10 Res Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
US12213958B2 (en) 2017-11-17 2025-02-04 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
US20220111019A1 (en) * 2018-09-19 2022-04-14 Virginia Tech Intellectual Properties, Inc. Brca1 modulating compounds, formulations thereof, and uses thereof
US20230008508A1 (en) * 2019-12-10 2023-01-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Combination therapies for the treatment of cancer
CN112336716A (zh) * 2020-11-25 2021-02-09 四川大学华西医院 维生素c和双硫仑在制备抗肿瘤联合用药物中的用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4569836A (en) * 1981-08-27 1986-02-11 Gordon Robert T Cancer treatment by intracellular hyperthermia
JP2514500B2 (ja) * 1991-09-14 1996-07-10 呉羽化学工業株式会社 多剤耐性抑制剤及び発現阻害剤
AU3257297A (en) * 1996-06-11 1998-01-07 Novartis Ag Combination of a somatostatin analogue and a rapamycin
US5865722A (en) 1997-04-04 1999-02-02 Numotech, Incorporated Shape-adaptable topical hyperbaric oxygen chamber
US6299925B1 (en) * 1999-06-29 2001-10-09 Xel Herbaceuticals, Inc. Effervescent green tea extract formulation
US6376525B1 (en) * 2000-09-15 2002-04-23 Qingzhong Kong Method and composition for treating cancer using cellular organelle crystallizing agents
JP2004528278A (ja) * 2000-12-18 2004-09-16 ボード オブ レジェンツ，ザ ユニバーシティー オブ テキサス システム インサイチュヒドロゲルを用いた、局所領域の化学療法および放射線治療
WO2003012085A1 (en) * 2001-07-30 2003-02-13 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antigen presenting cells, method for their preparation and their use for cancer vaccines
US7435725B2 (en) * 2001-11-06 2008-10-14 The Quigly Corporation Oral compositions and methods for prevention, reduction and treatment of radiation injury
US20030105104A1 (en) * 2001-11-27 2003-06-05 Burzynski Stanislaw R. Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy
US6572897B1 (en) * 2002-07-03 2003-06-03 Vitacost.Com, Inc. Insulin sensitivity maintenance and blood sugar level maintenance formulation for the prevention and treatment of diabetes
JP2007504131A (ja) * 2003-08-29 2007-03-01 エートン ファーマ インコーポレーティッド 癌の組み合わせ処置法
EP1571225A1 (en) * 2004-03-02 2005-09-07 PrimaGen Holding B.V. Diagnosis of a disease and monitoring of therapy using the AC133 gene
US20060045912A1 (en) * 2004-08-30 2006-03-02 Peter Truog 4-phenylbutyric acid controlled-release formulations for therapeutic use
JP2006298781A (ja) * 2005-04-15 2006-11-02 Geno Membrane:Kk エストロン３硫酸トランスポーター活性阻害剤
WO2007114697A1 (en) * 2006-03-31 2007-10-11 Erasmus University Medical Center Rotterdam Novel composition for tumor growth control
EP1847274A1 (en) * 2006-04-21 2007-10-24 CIPROSA LLC - Corporate Creations Network, Inc. Association of phenylbutyrate, ATRA and cytidine and its use in anti-tumour therapy
EP2040708B1 (en) * 2006-07-17 2018-03-14 Thomas Christian Lines Quercetin-containing compositions
EP2626067A1 (en) * 2006-12-26 2013-08-14 Pharmacyclics, Inc. Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
US20080305096A1 (en) * 2007-06-07 2008-12-11 Unicity International, Inc. Method and composition for providing controlled delivery of biologically active substances
WO2009046377A2 (en) * 2007-10-04 2009-04-09 Medistem Laboratories, Inc. Compositions and methods of stem cell therapy for autism
CA2716321A1 (en) * 2008-02-21 2009-08-27 The Regents Of The University Of Colorado Methods for treating cancer using combination therapy
EP2306996A1 (en) * 2008-07-18 2011-04-13 Novartis AG Use of hdac inhibitors for the treatment of hodgkin's disease
US20100316733A1 (en) * 2009-06-15 2010-12-16 Locklear Kenneth R Hyperbaric Oxygen Therapy and Treatment Method

Also Published As

Publication number Publication date
MX2014000150A (es) 2014-05-14
KR102020939B1 (ko) 2019-09-11
KR20190107166A (ko) 2019-09-18
AU2016269491B2 (en) 2018-08-30
PL2729008T3 (pl) 2017-10-31
WO2013006821A1 (en) 2013-01-10
JP2017105797A (ja) 2017-06-15
CN103796514A (zh) 2014-05-14
JP2014518274A (ja) 2014-07-28
CA2839727C (en) 2023-10-17
IN2014DN00195A (enExample) 2015-06-05
KR20140076546A (ko) 2014-06-20
CN109675041A (zh) 2019-04-26
RU2014101261A (ru) 2015-08-20
EP3326625A1 (en) 2018-05-30
EP2729008B1 (en) 2017-04-05
MX354383B (es) 2018-03-02
AU2012278813A1 (en) 2014-01-30
US20170014376A1 (en) 2017-01-19
EP2729008A4 (en) 2014-10-29
RU2644635C2 (ru) 2018-02-13
JP2018203767A (ja) 2018-12-27
AU2012278813B2 (en) 2016-09-08
CA2839727A1 (en) 2013-01-10
US20200206183A1 (en) 2020-07-02
ES2630306T3 (es) 2017-08-21
AU2016269491A1 (en) 2017-01-05
EP2729008A1 (en) 2014-05-14
US20130011488A1 (en) 2013-01-10
JP6401317B2 (ja) 2018-10-10

Similar Documents

Publication Publication Date Title
JP6401317B2 (ja) がんを治療するためのシステム、方法、および製剤
RU2640115C2 (ru) Фармацевтические композиции замещенных хиназолинонов
US20250017899A1 (en) Method of treating cancer with combinations of histone deacetylase inhibitors (hdaci) substances
JP2018535939A (ja) Ｎａｓｈ関連肝臓癌を治療するためのｅｐ４受容体拮抗薬の使用
AU2018206907A1 (en) Prophylactic and therapeutic drug for nonalcoholic fatty liver disease
RU2574009C2 (ru) Лекарственное средство для предотвращения и/или лечения гепатоклеточной карциномы
KR20210139293A (ko) 폐동맥 고혈압 및 연관 폐동맥 고혈압 치료방법 및 매일 투여
CN102441168B (zh) 含芹菜素及芹菜素类衍生物和Bcl-2抑制剂的药物组合物及其在制备治疗癌症的药物中的应用
EP3429572B1 (en) Combination therapy for proliferative diseases
WO2014047782A1 (zh) 含有白藜芦醇及白藜芦醇类衍生物和Bcl-2抑制剂的药物组合物及其应用
WO2019098288A1 (ja) 抗腫瘍剤及び配合剤
CN108403701B (zh) 二氢雷公藤红素在制备预防或治疗血液肿瘤疾病的药物中的用途
TWI538672B (zh) 應用二甲雙胍與丁酸鈉於ｋｒａｓ基因突變癌症治療之用途、醫藥組合物與醫藥套組
CN105530929B (zh) 3‑羧基‑n‑乙基‑n,n‑二甲基丙‑1‑铵或其药学上可接受的盐在预防和治疗糖尿病中的用途
Dunk 517 AQ4N mediated potentiation of chemoradiotherapy in human lung tumour xenografts
CN101137386A (zh) 肝癌的治疗方法
WO2014047783A1 (zh) 含有雷公藤甲素及雷公藤甲素类衍生物和Bcl-2抑制剂的药物组合物及其应用

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20140514

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140514

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150624

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160421

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160714

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20161021

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161222

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170123

R150 Certificate of patent or registration of utility model

Ref document number: 6082737

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250